Trials / Completed
CompletedNCT05822830
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 751 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | Semaglutide | Administered SC |
Timeline
- Start date
- 2023-04-21
- Primary completion
- 2024-11-13
- Completion
- 2024-11-13
- First posted
- 2023-04-21
- Last updated
- 2025-11-26
- Results posted
- 2025-11-26
Locations
32 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05822830. Inclusion in this directory is not an endorsement.